Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain

Cardiovascular Drugs and Therapy

Volumn 26, Issue 3, 2012, Pages 257-263

  Heusch, Gerd ^a   Schulz, Rainer ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cerebral ischemia; Dronedarone; Myocardial ischemia; Reperfusion; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; DRONEDARONE;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CELL PROTECTION; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY OBSTRUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART RATE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; RISK REDUCTION; STROKE;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BRAIN ISCHEMIA; HUMANS; MYOCARDIAL ISCHEMIA; REPERFUSION INJURY;

EID: 84864458151     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6379-z     Document Type: Article

References (71)

1. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212-23.
2. Watanabe Y, Kimura J. Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricularmyocytes. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:371-6.
3. Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:347-56.
4. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78.
5. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: Benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589-601. (Pubitemid 351535988)
6. Heusch G, Yoshimoto N, Müller-Ruchholtz ER. Effects of heart rate on hemodynamic severity of coronary artery stenosis in the dog. Basic Res Cardiol. 1982;77:562-73. (Pubitemid 12004641)
7. Heusch G, Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflugers Arch. 1983;397:284-9. (Pubitemid 13054409)
8. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56:1973-83.
9. Neill WA, Phelps NC, Oxendine JM, Mahler DJ, Sim DN. Effect of heart rate on coronary blood flow distribution in dogs. Am J Cardiol. 1973;32:306-12.
10. Guth BD, Heusch G, Seitelberger R, Ross Jr J. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987;60:738-46. (Pubitemid 17098139)
11. Guth BD, Heusch G, Seitelberger R, Ross Jr J. Elimination of exercise-induced regional myocardial dysfunction by a bradycardic agent in dogs with chronic coronary stenosis. Circulation. 1987; 75:661-9. (Pubitemid 17026059)
12. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine-protection beyond heart rate reduction. Eur Heart J. 2008;29:2265-75.
13. Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent-electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol. 1995;25:252-61.
14. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-99. (Pubitemid 47367078)
15. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156
16. Herrmann S, Layh B, Ludwig A. Novel insights into the distribution of cardiac HCN channels: An expression study in the mouse heart. J Mol Cell Cardiol. 2011;51:997-1006.
17. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: Anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279:25-32.
18. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16.
19. Heusch G. A BEAUTIFUL lesson-ivabradine protects from ischaemia, but not from heart failure: Through heart rate reduction or more? Eur Heart J. 2009;30:2300-1.
20. Wichmann J, Ertl G, HohneW, Schweisfurth H,Wernze H, Kochsiek K. Alpha-receptor restriction of coronary blood flow during atrial fibrillation. Am J Cardiol. 1983;52:887-92. (Pubitemid 13023781)
21. Wichmann J, Ertl G, Rudolph G, Kochsiek K. Effect of experimentally induced atrial fibrillation on coronary circulation in dogs. Basic Res Cardiol. 1983;78:473-91. (Pubitemid 13018718)
22. Ertl G, Wichmann J, Kaufmann M, Kochsiek K. Alpha-receptor constriction induced by atrial fibrillation during maximal coronary dilatation. Basic Res Cardiol. 1986;81:29-39. (Pubitemid 16108836)
23. Heusch G, Deussen A, Schipke J, Thdmer V. a1- and a2-Adrenoceptor- mediated vasoconstriction of large and small canine coronary arteries in vivo. J Cardiovasc Pharmacol. 1984;6:961-8. (Pubitemid 14023353)
24. Baumgart D, Haude M, Goerge G, Liu F, Ge J, Gro?e-Eggebrecht C, et al. Augmented a-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090-7. (Pubitemid 29196791)
25. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on the perfusion of stenotic coronary arteries in the dog. Circ Res. 1983;53:8-15. (Pubitemid 13031763)
26. Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross Jr J. Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436-42. (Pubitemid 18078682)
27. Heusch G. a -Adrenergic mechanisms in myocardial ischemia. Circulation. 1990;81:1-13.
28. Gregorini L, Marco J, Kozàkovà M, Palombo C, Anguissola GB, Marco I, et al. a-Adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482-90. (Pubitemid 29061862)
29. Gregorini L,Marco J, Farah B, Bernies M, Palombo C, Kozakova M, et al. Effects of selective a1- and a2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation. 2002;106:2901-7. (Pubitemid 35424739)
30. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. a-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689-94. (Pubitemid 30094742)
31. Bukowska A, Hammwohner M, Sixdorf A, Schild L, Wiswedel I, Rohl FW, et al. Dronedarone preventsmicrocirculatory abnormalities in the left ventricle during atrial tachypacing. Br J Pharmacol. 2011. doi:10.1111/j.1476-5381.2011. 01784.x.
32. Himmel HM, Dobrev D, Grossmann M, Ravens U. Ndesethylamiodarone modulates intracellular calcium concentration in endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:489-96.
33. GrossmanM, Dobrev D, KirchW. Amiodarone causes endotheliumdependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther. 1998;64:302-11. (Pubitemid 28462291)
34. Skyschally A, Heusch G. Reduction of myocardial infarct size by dronedarone in pigs-a pleiotropic action? Cardiovasc Drugs Ther. 2011;25:197-201.
35. Ludwig A, Zong X, Stieber J, Hullin R, Hofmann F, Biel M. Two pacemaker channels from human heart with profoundly different activation kinetics. EMBO J. 1999;18:2323-9. (Pubitemid 29213266)
36. El Chemaly A, Magaud C, Patri S, Jayle C, Guinamard R, Bois P. The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes. J Cardiovasc Electrophysiol. 2007;18:1190-6.
37. Suffredini S, Stillitano F, Comini L, Bouly M, Brogioni S, Ceconi C, et al. Long term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. Br J Pharmacol. 2012; 165:1457-66.
38. Yu X, Chen XW, Zhou P, Yao LJ, Liu T, Zhang B, et al. Calcium influx through I-f channels in rat ventricular myocytes. Am J Physiol-Cell Physiology. 2007;292:C1147-55. (Pubitemid 46440399)
39. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: Cardiovascular protection beyond heart rate reduction. Br J Pharmacol. 2008;155:970-1.
40. Inserte J, Garcia-Dorado A, Ruiz-Meana M, Padilla F, Barrabés JA, Pina P, et al. Effect of inhibition of Na+/Ca2+ exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res. 2002;55:739-48.
41. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, et al. Translating novel strategies for cardioprotection: The hatter workshop recommendations. Basic Res Cardiol. 2010; 105:677-86.
42. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. Postconditioning and protection fromreperfusion injury: Where do we stand? Cardiovasc Res. 2010;87:406-23.
43. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, et al. New horizons in cardioprotection: Recommendations from the 2010 National Heart, Lung, and Blood InstituteWorkshop. Circulation. 2011;124:1172-9.
44. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, et al. Analysis of stroke in Athena: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-80.
45. Christiansen CB, Torp-Pedersen C, Kober L. Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. Clin Interv Aging. 2010;5:63-9.
46. Dagres N, Varounis C, Iliodromitis EK, Lekakis JP, Rallidis LS, nastasiou-Nana M. Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: A systematic review and meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2011;Epub ahead of print.
47. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87. (Pubitemid 351860860)
48. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76.
49. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 1999;22:391-7. (Pubitemid 29453643)
50. Tatlisumak T, Carano RA, Takano K, MeilerMR, Li F, Sotak CH, et al. Broad-spectrum cation channel inhibition by LOE 908 MS reduces infarct volume in vivo and postmortem in focal cerebral ischemia in the rat. J Neurol Sci. 2000;178:107-13.
51. Park HS, Lee BK, Park S, Kim SU, Lee SH, Baik EJ, et al. Effects of sabiporide, a specific Na+/H+exchanger inhibitor, on neuronal cell death and brain ischemia. Brain Res. 2005;1061:67-71. (Pubitemid 41532347)
52. Aoki Y, Tamura M, Itoh Y, Seto T, Nonaka K, Mukai H, et al. Effective plasma concentration of a novel Na+/Ca2+ channel blocker NS-7 for its cerebroprotective actions in rats with a transient middle cerebral artery occlusion. J Pharmacol Exp Ther. 2001;296:306-11. (Pubitemid 32112454)
53. Chen CM, Liu SH, Lin-Shiau SY. Honokiol, a neuroprotectant against mouse cerebral ischaemia, mediated by preserving Na+, K+-ATPase activity and mitochondrial functions. Basic Clin Pharmacol Toxicol. 2007;101:108-16.
54. Candelario-Jalil E. Injury and repair mechanisms in ischemic stroke: Considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs. 2009;10:644-54.
55. Shi H. Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Curr Med Chem. 2009;16:4593-600.
56. Adluri RS, Thirunavukkarasu M, Dunna NR, Zhan L, Oriowo B, Takeda K, et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice. Antioxid Redox Signal. 2011;15:1789-97.
57. Ogle ME, Gu X, Espinera AR, Wei L. Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1alpha. Neurobiol Dis. 2012;45:733-42.
58. Yeh SH, Ou LC, Gean PW, Hung JJ, ChangWC. Selective inhibition of early-but not late-expressed HIF-1alpha is neuroprotective in rats after focal ischemic brain damage. Brain Pathol. 2011;21:249-62.
59. Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: Lessons from animal models. Metab Brain Dis. 2004;19:151-67. (Pubitemid 39361178)
60. Engelhorn T, Schwarz MA, Heusch G, Doerfler A, Schulz R. Reduction of cerebral infarct size by dronedarone. Cardiovasc Drugs Ther. 2011;25:523-9.
61. Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011;5:103-19.
62. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165:1185-91. (Pubitemid 40723655)
63. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.
64. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report fromthe Stockholmcohort of atrial fibrillation. Eur Heart J. 2010;31:967-75.
65. Nieuwlaat R, Hohnloser SH, Connolly SJ. Effect of dronedarone in patients with permanent atrial fibrillation during the ATHENA study. Eur Heart J. 2011;32:618.
66. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke. 2008;39:2929-35.
67. Lip GYH, Frison L, Grind M, On behalf of the SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752-9. (Pubitemid 46439230)
68. Lees AD, Wilson J, Orchard CH, Orchard MA. Ouabain enhances basal and stimulus-induced cytoplasmic calcium concentrations in platelets. Thromb Haemost. 1989;62:1000-5.
69. Chirinos JA, Castrellon A, Zambrano JP, Jimenez JJ, JyW, Horstman LL, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2:525-9. (Pubitemid 40521368)
70. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Inaugural article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008;105:19579-86.
71. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 2010;24:1759-67.